PubRank

Shenhong Wu

Author PubWeight™ 57.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008 7.13
2 Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011 6.14
3 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007 3.47
4 Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009 2.87
5 Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008 2.22
6 The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 2005 1.88
7 Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009 1.82
8 Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol 2010 1.50
9 Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010 1.50
10 Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010 1.48
11 Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 2013 1.45
12 Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008 1.39
13 Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009 1.34
14 Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010 1.31
15 The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2011 1.00
16 Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 2010 0.98
17 Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 2011 0.97
18 Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 2013 0.96
19 Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 2012 0.96
20 Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007 0.95
21 Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 2009 0.94
22 Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol 2013 0.90
23 Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. Am J Clin Oncol 2014 0.89
24 Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur J Haematol 2013 0.88
25 Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009 0.88
26 The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2013 0.88
27 The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol 2012 0.86
28 Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Invest 2015 0.85
29 Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer 2007 0.84
30 Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis. Acta Oncol 2011 0.83
31 The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2011 0.83
32 Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk 2013 0.83
33 Inverse association between eczema and meningioma: a meta-analysis. Cancer Causes Control 2011 0.82
34 The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013 0.81
35 Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat 2012 0.80
36 Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report. J Med Case Rep 2010 0.78
37 Replacement of the membrane proximal region of I-A(d) MHC class II molecule with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity. J Immunol Methods 2005 0.78
38 Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatol Ther 2013 0.76
39 Novel therapies in genitourinary cancer: an update. J Hematol Oncol 2008 0.75
40 Alopecia with endocrine therapies in patients with cancer. Oncologist 2013 0.75
41 Controversial role of bevacizumab in the development of venous thromboembolic events. J Clin Oncol 2011 0.75
42 Anticancer therapy-induced adverse events: practicing damage control. Expert Opin Drug Saf 2012 0.75
43 Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials. Acta Oncol 2014 0.75